teverelix
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 19, 2018 (NCT03781947)
Timeline
Indications
Mechanism of action
- Gonadotropin-releasing hormone receptorANTAGONIST
GNRHR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O- Mol. weight
- 1459.16 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103945 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04693507 | Phase 2 | Mar 4, 2021 | Antev Ltd., Government of Lithuania |
| NCT03781947 | Phase 1 | Nov 19, 2018 | Antev Ltd., Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antev Ltd. | For profit | 2 | 2 | 2 | 2018 |
| Government of Lithuania | Government | 1 | 0 | 1 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1